Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor Response Rate”

204 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 204 results

Not applicableLooking for participantsNCT06635954
What this trial is testing

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Who this might be right for
CancerImmunotherapyPD-1+2 more
Oxford Biodynamics Inc. 2,000
Testing effectiveness (Phase 2)Study completedNCT01915602
What this trial is testing

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Who this might be right for
Carcinoma, Hepatocellular
Bayer 14
Testing effectiveness (Phase 2)UnknownNCT01337531
What this trial is testing

Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)

Who this might be right for
Polycystic Ovary Syndrome
Genesis Center for Fertility & Human Pre-Implantation Genetics 200
Large-scale testing (Phase 3)Study completedNCT00826644
What this trial is testing

Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient

Who this might be right for
Carcinoma, Small Cell
Chonnam National University Hospital 147
Testing effectiveness (Phase 2)Looking for participantsNCT06134232
What this trial is testing

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Dendreon 400
Testing effectiveness (Phase 2)Study completedNCT00802880
What this trial is testing

Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma

Who this might be right for
Sarcoma
Washington University School of Medicine 80
Testing effectiveness (Phase 2)Study completedNCT00919399
What this trial is testing

Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant

Who this might be right for
Breast Neoplasms
Institut Claudius Regaud 15
Not applicableNot Yet RecruitingNCT06035471
What this trial is testing

Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study

Who this might be right for
Pathological Response Rate, Circulating Tumour DNA
Erasmus Medical Center 75
Testing effectiveness (Phase 2)Study completedNCT00328861
What this trial is testing

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Who this might be right for
Metastatic MelanomaMetastatic Kidney Cancer
National Cancer Institute (NCI) 8
Testing effectiveness (Phase 2)Looking for participantsNCT06848842
What this trial is testing

Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

Who this might be right for
Colorectal Liver Metastases
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 40
Not applicableStudy completedNCT00590941
What this trial is testing

Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma

Who this might be right for
LymphomaDiffuse Large Cell
Washington University School of Medicine 52
Testing effectiveness (Phase 2)UnknownNCT05760196
What this trial is testing

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Who this might be right for
Objective Response Rate
Xiangpan Li 56
Testing effectiveness (Phase 2)Study completedNCT00385996
What this trial is testing

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-small Cell Lung
Weill Medical College of Cornell University 22
Testing effectiveness (Phase 2)Looking for participantsNCT04698785
What this trial is testing

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

Who this might be right for
Bone SarcomaOsteosarcoma
Centre Leon Berard 36
Large-scale testing (Phase 3)Not Yet RecruitingNCT07134218
What this trial is testing

Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer

Who this might be right for
Rectal Cancer
Changhai Hospital 180
Testing effectiveness (Phase 2)Study completedNCT01037127
What this trial is testing

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Who this might be right for
Cancer
GlaxoSmithKline 97
Not applicableUnknownNCT03892577
What this trial is testing

Real-world Study for Patients With Advanced Hepatobiliary Tumors

Who this might be right for
Objective Response RateProgression-free SurvivalOverall Survival+4 more
Peking Union Medical College Hospital 3,000
Testing effectiveness (Phase 2)UnknownNCT05310383
What this trial is testing

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Who this might be right for
Recurrent Cervical CarcinomaMetastatic Cervical CarcinomaPersistent Cervical Carcinoma+7 more
Lei Li 58
Testing effectiveness (Phase 2)Study completedNCT00545688
What this trial is testing

Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 417
Testing effectiveness (Phase 2)Looking for participantsNCT06034561
What this trial is testing

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed Remission
Instituto do Cancer do Estado de São Paulo 50
Load More Results